Performance of clinical risk scores and prediction models to identify pathogenic germline variants in patients with advanced prostate cancer
Authors (first, second and last of 16)
Collection
Current Management and Future Treatment Strategies for Patients with Metastatic Hormone-Sensitive Prostate Cancer
This collection was published as Topical Section in Volume 41, Issue 8, September 2023
Editors
-
Pawel Rajwa, MD, PhD, Medical University of Vienna, Austria
Department of Urology, Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria Department of Urology, Medical University of Silesia, 3 Maja Street 13-15, 41-800, Zabrze, Poland
-
Fahad Quhal, MD, Medical University of Vienna, Austria
Department of Urology, Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria Department of Urology, King Fahad Specialist Hospital, Dammam, Saudi Arabia
-
Igor Tsaur, MD, Johannes Gutenberg University, Germany
Department and Outpatient Clinic for Urology and Pediatric Urology, University Medical Center of Johannes Gutenberg University Mainz, Mainz, Germany
Articles (10 in this collection)
-
-
-
Oncological and perioperative outcomes of surgery with or without metastasis-directed therapy as part of a multimodal treatment in men with de-novo oligometastatic prostate cancer
Authors (first, second and last of 15)
-
Personalizing approaches to the management of metastatic hormone sensitive prostate cancer: role of advanced imaging, genetics and therapeutics
Authors (first, second and last of 9)
-
What is the ideal combination therapy in de novo, oligometastatic, castration-sensitive prostate cancer?
Authors (first, second and last of 17)
-
Real-world comparison of Docetaxel versus new hormonal agents in combination with androgen-deprivation therapy in metastatic hormone-sensitive prostate cancer descrying PSA Nadir ≤ 0.05 ng/ml as marker for treatment response
Authors (first, second and last of 8)
-
Focal therapy for primary tumor and metastases in de novo or recurrent oligometastatic prostate cancer: current standing and future perspectives
Authors (first, second and last of 10)
-
Current status and future perspectives of the managements of metastatic hormone-sensitive prostate cancer
Authors (first, second and last of 7)
-
-
Combination of docetaxel versus nonsteroidal antiandrogen with androgen deprivation therapy for high-volume metastatic hormone-sensitive prostate cancer: a propensity score-matched analysis
Authors (first, second and last of 22)
